Hybrid Drug Discovery Chemistry is a dynamic conference for medicinal chemists working in pharma and biotech. Focused on discovery and optimization challenges of small molecule drug candidates, this event provides many exciting opportunities for scientists. Our CEO Gregg Siegal attended the event and participated in many interesting and educational discussions. Conference website
8th RSC-BMCS Fragment-based Drug Discovery Meeting
Hybrid ZoBio attended the 8th RSC-BMCS Fragment-based Drug Discovery meeting which was taking place in Cambridge on the 27-29 March 2022. The meeting focused on case studies in Fragment-based Drug Discovery that have delivered compounds to late stage medicinal chemistry, preclinical or clinical programs. Great scientific program and fantastic atmosphere delivered a truly memorable conference!…
The Insidious Underbelly of Protein Aggregation
It is well known, and accepted, that it is essential to have “high quality” protein at the outset of a target based, small molecule drug discovery campaign. But what does “high quality” mean?
Certainly biological activity is a must. A high degree of purity (typically ≥95%) is another crucial requirement. Most often “purity” is defined based on the presence of other proteins in the preparation, but the presence of small molecules, whether or not of biological origin, also needs to be considered. However, the aggregation state is only rarely considered, and yet it significantly impacts…
Eurostars DiscoveRNA Project Awarded!
RNA as a potential drug target is currently gaining a lot of interest, but the right technologies are not all in place to successfully pursue them. ZoBio and its partner ETH Zurich have been awarded with a €1.2 million EUREKA Eurostars grant, to establish an automated pipeline enabling…